Philipp Novoszel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Philipp Novoszel has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Maria Sibilia
Medical University of Vienna
17 shared publications - Dana Krauß
Center for Cancer Research & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria
15 shared publications - Martin Holcmann
Center for Cancer Research & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria
15 shared publications - Anne-Sophie Ebner
Center for Cancer Research & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria
14 shared publications - Bernadette Mödl
Center for Cancer Research & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria
14 shared publications - Birgit Strobl
Centre of Biological Sciences, University of Veterinary Medicine Vienna, Vienna, Austria
14 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Tyk2 deletion in AKP organoids has no effect on CRLM
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Tyk2 deletion in AKP organoids has no effect on CRLM
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Number of resident and migratory cDCs is unchanged in the tumor-draining lymph nodes of metastases-bearing TYK2-/- host mice
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Number of resident and migratory cDCs is unchanged in the tumor-draining lymph nodes of metastases-bearing TYK2-/- host mice
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Immunophenotyping of established metastases by flow cytometry in TYK2-/- and TYK2Δhem host mice
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Immunophenotyping of established metastases by flow cytometry in TYK2-/- and TYK2Δhem host mice
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
MRNA expression of markers for immune cell identity and angiogenic factors in healthy and metastases-bearing livers of TYK2flox/flox and TYK2Δhem host mice
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
MRNA expression of markers for immune cell identity and angiogenic factors in healthy and metastases-bearing livers of TYK2flox/flox and TYK2Δhem host mice
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Expression of TYK2 in human CRC-derived LAMP3+ CCR7+ cDCs
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Expression of TYK2 in human CRC-derived LAMP3+ CCR7+ cDCs
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Evaluation of TYK2 deletion in conditional mouse models
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Evaluation of TYK2 deletion in conditional mouse models
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
TYK2 in macrophages, granulocytes, Kupffer cells, T cells or NK cells is not required for immunosurveillance of CRLM
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
TYK2 in macrophages, granulocytes, Kupffer cells, T cells or NK cells is not required for immunosurveillance of CRLM
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Altered immunophenotype of micrometastatic lesions in TYK2Δhem host mice
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Altered immunophenotype of micrometastatic lesions in TYK2Δhem host mice
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
TYK2 deficiency in host mice promotes liver metastasis of AKP organoids seeded via the portal vein
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
TYK2 deficiency in host mice promotes liver metastasis of AKP organoids seeded via the portal vein
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Data from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Colorectal cancer liver metastasis (CRLM) is a major clinical problem. The regulators of immunosurveillance of CRLM could hold potential for developing therapeutic strategies to prevent or treat metastasis. In this study, using a murine colorectal cancer organoid-based transplantation model, we identified TYK2 as a key factor controlling CRLM. Evaluation of the effects of Tyk2 deletion in different subsets of immune cells and in colorectal cancer cells demonstrated that TYK2 was not required in cancer cells, macrophages, NK cells, T cells, or Kupffer cells. Instead, TYK2 controlled CRLM via a dendritic cell–dependent mechanism that relied on MHC-I–mediated cross-presentation of antigens to CD8+ T cells. Analysis of single-cell RNA sequencing data from primary colorectal cancer and CRLM revealed that TYK2 was predominantly expressed in a dendritic cell population destined to present antigens in tumor-draining lymph nodes. Treatment with the TYK2 inhibitor deucravacitinib, which is approved by the FDA for treating plaque psoriasis and is under clinical investigation for other autoimmune diseases, promoted CRLM. Together, these data demonstrate that TYK2 controls CRLM immunosurveillance, which should be carefully considered when treating patients with TYK2 inhibitors.Significance:TYK2 restricts the metastasis of colorectal tumors to the liver by supporting dendritic cell-dependent induction of antitumor CD8+ T cells, which could impact the use of TYK2 inhibitors in patients.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
Colorectal cancer liver metastasis (CRLM) is a major clinical problem. The regulators of immunosurveillance of CRLM could hold potential for developing therapeutic strategies to prevent or treat metastasis. In this study, using a murine colorectal cancer organoid-based transplantation model, we identified TYK2 as a key factor controlling CRLM. Evaluation of the effects of Tyk2 deletion in different subsets of immune cells and in colorectal cancer cells demonstrated that TYK2 was not required in cancer cells, macrophages, NK cells, T cells, or Kupffer cells. Instead, TYK2 controlled CRLM via a dendritic cell–dependent mechanism that relied on MHC-I–mediated cross-presentation of antigens to CD8+ T cells. Analysis of single-cell RNA sequencing data from primary colorectal cancer and CRLM revealed that TYK2 was predominantly expressed in a dendritic cell population destined to present antigens in tumor-draining lymph nodes. Treatment with the TYK2 inhibitor deucravacitinib, which is approved by the FDA for treating plaque psoriasis and is under clinical investigation for other autoimmune diseases, promoted CRLM. Together, these data demonstrate that TYK2 controls CRLM immunosurveillance, which should be carefully considered when treating patients with TYK2 inhibitors.Significance:TYK2 restricts the metastasis of colorectal tumors to the liver by supporting dendritic cell-dependent induction of antitumor CD8+ T cells, which could impact the use of TYK2 inhibitors in patients.